News 2017

  • Antikor Advances Breakthrough Fragment Drug Conjugate (FDC) Technology

    13 November 2017

    13/11/2017 Antikor Biopharma Limited (Antikor), a leader in developing and advancing Antibody Fragment-Drug Conjugates (FDCs), will be presenting new data at the 9th Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon on 14th November, 2017 ( www.pegsummiteurope.com ). Dr... read more



  • AKL Research and Development receive CTA for a trial of APPA in Osteoarthritis

    23 October 2017

    23/10/2017 AKL Research and Development Ltd . based at the Stevenage Bioscience Catalyst, in partnership with The University of Liverpool, has received clinical trial authorisation (CTA) to commence a phase I clinical trial to test AKL’s lead clinical candidate, APPA, as a potential... read more



  • GSK and Plasticell to manufacture haematopoietic cells from iPSC

    19 October 2017

    19/10/2017 GSK has entered a collaboration to use UK-based firm Plasticell’s combinatorial stem cell screening technology, CombiCult, to develop haematopoietic cells from induced pluripotent stem cells (iPSC). Plasticell is a biotechnology company that specialises in stem cell... read more



  • Kandy Therapeutics Launched to Focus on a Breakthrough New Product in Women's Health

    27 September 2017

    27/09/2017 KaNDy Therapeutics has been launched today to maximise the value of NT-814, a potential breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions and is backed by internationally recognised life sciences investors: Advent Life Sciences,... read more



  • New licensing agreement for UCL technology to combat antimicrobial res

    27 September 2017

    27/09/2017 The alarming rise and spread of antimicrobial resistance is an increasing global challenge and there is considerable interest and an acknowledged benefit in the targeted delivery of antimicrobial agents. UCL Business and AGA Nanotech Ltd have concluded a licensing... read more



  • New Reports Prove UK is 'Science Powerhouse'

    21 September 2017

    21/09/2017 LORD PRIOR LAUNCHES NEW SCIENCE AND INNOVATION AUDITS Business Minister Lord Prior has launched the latest wave of Science and Innovation Audits at Venturefest East today (Thursday 21 st September 2017), including one developed for the East of England. Science &... read more



  • TrakCel announces partnership with Cell and Gene Therapy Catapult to i

    7 September 2017

    7/09/2017 TrakCel solution integration with Cell and Gene Therapy Catapult manufacturing centre enables needle-to-needle supply chain management at any scale London, UK, September 7, 2017- The Cell and Gene Therapy Catapult (CGT Catapult) today announces a partnership agreement with... read more



  • SBC celebrates its fifth birthday with new publication to showcase its

    6 September 2017

    Five Years of Innovation with Impact' highlights SBC influence on UK biotech sector Stevenage, UK, September 6 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is marking its fifth birthday with the launch of an... read more



  • New investment in Cell and Gene Therapy Catapult manufacturing centre

    1 September 2017

    £12m Industrial Strategy Challenge Fund award will double current capacity of theCell and Gene Therapy Catapult manufacturing centre in Stevenage, enabling more companies to develop cell therapy products for the global market. CGT Catapult holds unique expertise across the cell and gene... read more



  • LifeArc, Dstl and CDRD collaborate to identify antibacterial drug targ

    30 June 2017

    LifeArc, the UK medical research charity previously known as MRC Technology, is working alongside the government’s Defence Science and Technology Laboratory and Canada’s Centre for Drug Research and Development (CDRD) to identify new antibacterial drug targets. This parties have... read more



  • Cell Medica acquisition of WT1 T-cell therapy

    20 June 2017

    Acquisition transfers intellectual property and commercialisation rights to promising cancer immunotherapy, further development will take place at the Cell and Gene Therapy Catapult UK manufacturing centre. London, 20 June 2017 - The Cell and Gene Therapy Catapult (CGT Catapult) today... read more



  • LifeArc set to transform medical research landscape

    15 June 2017

    LifeArc, the UK medical research charity previously known as MRC Technology 1 , today announced ambitious plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million 2 over the next five years,... read more



  • MRC Technology and Biocartis initiate development of liquid biopsy tes

    7 June 2017

    Partnership aimed at the development of molecular diagnostic assays on Biocartis’ fully automated Idylla™ platform London (UK) / Mechelen (Belgium), 7 June 2017 – MRC Technology (‘MRCT’), a medical research charity, and Biocartis Group NV... read more



  • Good news for Hertfordshire life sciences cluster

    17 May 2017

    Hertfordshire’s thriving life sciences sector has been singled out for praise in a report on the British life sciences landscape. A recent workshop held by the Academy of Medical Sciences and the Association of the British Pharmaceutical Industry explored the changes taking place in drug... read more



  • Talking Medicines are launching the Medsmart App, available on Android

    11 May 2017

    Talking Medicines are launching the Medsmart App, available on Android and iOS in the app stores now. The Medsmart App gives users the ability to make smarter decisions about their medicines, taking control of their health. With audiovisual content explaining how their individual medicines work... read more



  • EMA grant LIfT 'ATMP Classification'

    2 May 2017

    The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP). LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a medical procedure) in an... read more



  • ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Progra

    24 April 2017

    Phase 2a RSV Challenge Study Planned for Q3 2017 London, UK, 24 th April 2017 / ReViral, a UK based biotechnology company focused on the discovery and development of antivirals for respiratory syncytial virus (RSV), announced today top-line safety and pharmacokinetic (PK) data from the... read more



  • Plasticell signs stem cell research collaborations with leading Singap

    28 March 2017

    28 March 2017, Stevenage UK: Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stemcell... read more



  • LIfT BioSciences Wins Medcity Award

    23 March 2017

    LIfT BioSciences has been announced as one of the winners of Medcity’s Collaborate to Innovate Award and grant. The focus for the project work with Professor Farzin Farzaneh, Professor of Molecular Medicine at King’s College London, is to develop in-vitro evidence that LIfT... read more



  • Fisher BioServices’ CryoHub to co-locate with manufacturing centre

    21 March 2017

    Fisher BioServices’ CryoHub to co-locate with the Cell and Gene Therapy Catapult manufacturing centre for seamless supply chain management and to accelerate cell and gene therapy production. London, 21 March 2017 – To help address the challenges surrounding supply chain... read more



  • Autifony Therapeutics obtains £1.3 million in funding from Innovate UK

    15 March 2017

    Stevenage, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for serious disorders of the central nervous system, today announced a new funding award of £895,000 from the Biomedical... read more



  • STEVENAGE BIOSCIENCE CATALYST'S CEO MARTINO PICARDO TO LEAVE AT THE EN

    13 March 2017

    Stevenage, UK, March 14 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, has announced that CEO Martino Picardo will be leaving at the end of June. Dr Picardo, SBC's first CEO, will return to his home base in Manchester... read more



  • East of England Science and Innovation Audit - Life Sciences Theme

    10 March 2017

    Report from kick-off meeting at Innovate UK East of England conference, February 21 The Life Sciences theme of the East of England Science and Innovation Audit has made substantial progress. We are continuing to seek views 1 from many of the key organisations in life sciences across the... read more



  • Apollo Therapeutics: Funding of Four Initial Projects and Operational

    22 February 2017

    First four drug discovery programmes now launched in collaboration with academics at all three partner universities - spanning a variety of disease areas and drug modalities Recruited highly experienced Project Directors with track records of delivering project success within big pharma ... read more



  • Clinical trial for new innovative Osteoarthritis drug

    16 February 2017

    The University of Liverpool, in partnership with AKL Research and Development Ltd , is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the most common type of arthritis inthe UK, affecting more than eight million people*, and is the... read more



  • Cancer Research Technology, UCL, and Tusk Therapeutics join forces to

    7 February 2017

    ​London and Stevenage, United Kingdom | February 7, 2017 CANCER RESEARCH TECHNOLOGY, Cancer Research UK’s commercial arm, Tusk Therapeutics, an immuno-oncology company and UCL (University College London) have signed a licence and collaboration agreement to research, develop and... read more



  • Plasticell increases flow of stem cell therapy pipeline Plasticell

    7 February 2017

    Plasticell founder named “Best CEO in the Stem Cell industry” by European CEO magazine 07January 2017, Stevenage UK: Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that the Company’s founder, Dr. Yen Choo, has been named... read more



  • SBC & East and North Hertfordshire NHS Trust launch clinical expertise

    6 February 2017

    Trust staff to provide clinical guidance to tenants & across SBC network Stevenage, UK, February 6 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, and the East and North Hertfordshire NHS Trust are pleased to... read more



  • LIfT BioSciences Joins Stevenage Bioscience Catalyst

    6 February 2017

    LIfT BioSciences has joined the UK's leading BioIncubator, Stevenage Bioscience Catalyst (SBC), for the UK's most promising SMEs in the healthcare space. The move will give LIfT Bio access to a spectrum of state-of-the-art translational research labs and development capabilities, including... read more



  • Stevenage Bioscience Catalyst is five years old

    1 February 2017

    Great start to sixth year as money raised by tenants exceeds £200m Stevenage, UK, February 1 2017 – Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve healthcare, is celebrating its fifth birthday. Opened in February 2012 to bring... read more



  • Ossianix receives milestone payment from Lundbeck for blood-brain barr

    26 January 2017

    Shark antibody technology has potential to deliver therapeutics across previously impermeable BBB 26 January 2017 - PHILADELPHIA, USA & STEVENAGE, UK: Ossianix Inc., which has generated a world leading platform for delivering biotherapeutic products into the CNS using the highly versatile... read more



  • East of England Science and Innovation Audit - Life Sciences Theme

    18 January 2017

    Commissioned by the Department of Business, Energy and Industrial Strategy (BEIS), Science and Innovation Audits ( SIAs ) are taking place across the UK. Their aims include pinpointing of areas of global competitive advantage, informing future science and innovation strategy, and the generation of... read more



  • Autifony Therapeutics announces positive results from Phase I study of

    10 January 2017

    Demonstrated dose dependent changes in Mismatch Negativity latency in healthy volunteers; Phase Ib Ketamine challenge study initiated in Manchester London, UK -10th January 2017 - Autifony Therapeutics Limited (“Autifony”),which ispioneering the development of novel... read more



  • NeRRe Therapeutics raises £23million in oversubscribed Series B financi

    5 January 2017

    NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round New funds to advance unique neurokinin receptor antagonist pipeline towards late-stage clinical development in common, chronicand debilitating respiratory and women’s health conditions. New... read more



  • Achilles Therapeutics starts 2017 with move to StevenageBioscience Cat

    Achilles Therapeutics starts 2017 with move to StevenageBioscience Cat

    4 January 2017

    Stevenage, UK, January 4 2017 – Achilles Therapeutics, which is focused on the development of novel cancer immunotherapies targeting neoantigens, has moved into its new headquarters at Stevenage Bioscience Catalyst (SBC), the open innovation campus driving collaboration to improve... read more










 



Stevenage Bioscience Catalyst is UCL's Business Partner of the Year

Watch: 

Stevenage Bioscience Catalyst is UCL's Business Partner of the Year 2015

Funding Partners: